Sutro Biopharma Inc. [NASDAQ:STRO] shares are showing some interesting activity. The company’s daily low is at $10.55 as the high is reaching $11.50.
If readers are not familiar, Sutro Biopharma Inc. is in the Healthcare sector under the Biotechnology industry. This week, we are watching the stock hit price per sales of 10.50 with an earning per share of -1.11.
As a reference point, the S&P 500 is trading 1.26% over the last 52 weeks, while STRO stock is trading -0.91%.
The Price is right
Holding a Market Cap of $422.05 million, Sutro Biopharma Inc. has seen a trading range over the last year of $6.00-$13.91.
For the last five days, STRO is down from its last closing price. The average shares trading hands each day is 302.37K.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for STRO. When we apply the Elder Force Index to Sutro Biopharma Inc., we are seeing an Elder Force Indicator number of 880911.91.
In the last quarter, STRO made a profit of 25.89 million. Sutro Biopharma Inc. also saw quarter revenue growth year over year of 11.24%.
Looking at popular technical indicators, the company’s 5-day moving average is 11.60 compared to the 50-day moving average of 2.10%. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. STRO currently holds a 9-day RSI of 51.80%, while 100-day RSI stands at 51.54%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. STRO’s 9-day MACD is -0.96 and the company’s 100-day MACD stands at 1.40.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 21.16% by insiders and 69.52% by institutions. Regarding institutional holdings, BVF Inc. owns 6.60%, while the second top holder, Eventide Asset Management LLC, currently owns 5.54%.
Over the last six months, insiders have sold 975 with the most recent transaction from Hallam Trevor, Chief Scientific Officer, with a sell at price 9.04 per share.
Overall, the recommended rating for STRO is Strong Buy. Currently, the company has 9 analysts watching the stock, and the average quarterly earnings estimate is -0.55. Quarterly revenue estimates are averaging 8.54M with the high estimate reaching 12M and the low at 5M.